Patent 10202366 was granted and assigned to Karyopharm Therapeutics Inc. on February, 2019 by the United States Patent and Trademark Office.
The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: